243results about How to "Delay disease progression" patented technology

Methods for slowing disease progression in an individual suffering from familial ALS are provided. Also provided are methods of increasing the survival time of an individual suffering from familial ALS. These methods employ antisense oligonucleotides targeted to SOD1, for use in inhibiting the expression of SOD1 in the central nervous system of an individual suffering from familial ALS.

The present invention relates to recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are novel simian adenoviruses having a low seroprevalence and high immunogenicity relative to other adenoviruses and vectors thereof. The invention also provides methods for production of the adenoviruses and for the treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).

A method of assessing the likelihood that a person who is asymptomatic for coronary artery disease does in fact have the disease is disclosed. The levels of an atherogenic protein and acute phase reactant and optionally of anti-atherogenic protein for an individual are obtained and compared to one or more cut-points related to those substances and, based on the comparison(s), an assessment is made of the likelihood that the individual has coronary artery disease. The atherogenic protein may be OxLDL, the acute phase reactant may be C-reactive protein or fibrinogen, and the anti-atherogenic protein may be HDL.

The invention relates to a special clinical nutrient composition for liver diseases and a preparation method of the composition. The special clinical nutrient composition comprises protein, fat, carbohydrate, dietary fibers, macro-elements, trace elements, vitamins, dietary essence, medicinal and edible components, natural plant compounds and new resource food, wherein the new resource food comprises hyriopsis cumingii polysacchride, and the medicinal and edible components comprise mint, Indian bread, barbary wolfberry fruits, common floweringquince fruits, common yam rhizome, mulberry fruits, spina date seeds and citrons. The preparation method includes the steps: preparing the components into powder in advance; uniformly mixing the powder to prepare corresponding dosage forms. The medicinal and edible components are subjected to water extraction, concentration and spray drying to prepare the powder, and the vitamins and the fat are microencapsulated into the powder. By screening and matching the components, the nutrient composition can provide needed energy, key nutrients and necessary trace elements for patients suffering from the liver diseases, the liver diseases are treated and liver cells are protected under the synergistic action of the components, and development of the liver diseases is slowed down.

This invention relates to the diagnosis and treatment of pre-Type 1 diabetes and Type-1 diabetes (T1D); particularly to the use of neuronal proteins as predictors of the disease; and most particularly to GFAP (glial fibrillary acidic protein); GAD65 (glutamic acid decarboxylase 65); NSE (neuron specific enolase; S100β and CNPase (2′, 3′-cyclic nucleotide 3′-phosphodiesterase) neuronal proteins useful for pre-Type 1 diabetes screening and / or staging.

There is described a system, method, and computer-readable medium having stored thereon executable program code for generating a final Cobb angle prediction for idiopathic scoliosis, the method comprising: receiving patient-specific 3D morphological spine parameters, a selected curve type, and a selected skeletal maturity; applying the patient-specific 3D morphological spine parameters, a selected curve type, and a selected skeletal maturity to a predictive model based on 3D morphological spine parameters, curve type, and skeletal maturity, and generating the final Cobb angle prediction by modeling a progression curve of the idiopathic scoliosis.

Provided are methods for selective extraction of cannabinoids, for example cannabidiol (CBD), from a plant source, by using tailored extraction media.

This invention relates generally to a synthetic medium for soilless propagation and growth of plants. More specifically, the synthetic medium components are formed in particular shapes and sizes of a polymer foam to optimize the several stages of plant propagation and growth. A method for utilizing these foam components is also disclosed for use in a standard glass house environment. Each step is optimized for a particular type of plant and its individual growth stage. The soilless medium preferred in this invention also allows for a dramatic reduction in scrap material disposal costs and problems as the preferred foam material reverts to powder form when compressed at up to an 80% volume reduction versus the foam state. These powders can be land-filled, recycled as soil additives or incinerated without environmental impact. Trays for handling foam material components and their lids prevent evaporation of moisture and are also reusable and the thermoplastic resins from which they are formed are also recyclable.

The present invention relates to compositions and methods for the treatment of amyotrophic lateral sclerosis. More specifically, the present invention relates to novel combinatorial therapies for treating amyotrophic lateral sclerosis or a related disorder.

The present invention relates to compositions and methods for the treatment of amyotrophic lateral sclerosis. More specifically, the present invention relates to novel combinatorial therapies for treating amyotrophic lateral sclerosis or a related disorder.

Provided are cannabinoid-loaded formulations, as well as processes for their preparation.

The present invention concerns a stable lipid assembly comprising a biologically active lipid having a hydrophobic region and a polar headgroup, wherein the atomic mass ratio between the headgroup and hydrophobic region is less than 0.3, and a lipopolymer having a hydrophobic lipid region and a polymer headgroup, wherein the atomic mass ratio between the headgroup and hydrophobic region is at least 1.5 and optionally a lipid matrix composed of liposome forming lipids. Specific lipid assemblies according to the invention comprise the biologically active lipid, ceramide, a lipid derivatized with polyethylene glycol (lipopolymer) and optionally in combination with a phospholipid (e.g. Egg phosphatidylcholine (EPC) and hydrogenated soybean phosphatidylcholine (HSPC)). The lipid assemblies of the invention exhibited a therapeutic effect in vitro in tumor cells as well as in vivo in animal models and they deliver the biologically active lipid to the disease site.

The invention relates to a composition containing Haematococcus pluvialis. The composition comprises the following components by weight: 1-40 parts of Haematococcus pluvialis, 1-10 parts of a Saussurea involucrata culture, 10-40 parts of acerola cherry powder and 40-80 parts of oligosaccharide. The composition provided by the invention can improve exercise tolerance and delay fatigue, and the mechanism of action is probably related to increase of the body's SOD content and decrease of the body's MDA content. Also, the composition has exercise tolerance improving and fatigue delaying effects superior to the prior art, and has a synergistic effect.

The present invention provides an ex vivo method of treating plasmacytoid dendritic cells (pDC) in Th2- or Th17-associated diseases by modulating the cytokine expression or secretion using interferon lambda (IFN-λ). For the Th-2 or Th17-associated diseases, pDC cells from a patient having the disease are exposed ex vivo with IFN-λ in an effective amount to inhibit cytokine releases. The IFN-λ exposed pDC are administered back into the patient. The present invention also provides a method of ex vivo IFN-λ treatment of pDC, in conjunction with co-administration of a composition comprising IFN-λ.

Oleanolic acid (3β-hiydroxyolean-12-en-28-oic acid) is a pentacyclic triterpene occurring in a large number of medicinal plants. The present invention is directed to the pharmacological application of the oleanolic acid, alone or in combination with other substances, in the treatment or prophylaxis of neurodegenerative diseases such as multiple sclerosis. The inventors have found that oleanolic acid, intraperitoneally administered once daily, reduces significantly the immuno-inflammatory and neurological symptoms associated with the experimental autoimmune encephalomyelitis, an experimental model of multiple sclerosis, delaying the onset and reducing the progression of the disease.

The invention provides a traditional Chinese medicine preparation for treating liver cancer, comprising the following raw medicines in parts by weight: 10-20 parts of acanthopanax, 10-20 parts of oldenlandia diffusa, 10-20 parts of radix astragali, 10-20 parts of cambogia, 10-20 parts of glossy privet fruit, 10-20 parts of white atractylodes rhizome, 10-20 parts of radix polygoni multiflori preparata, 10-20 parts of oriental wormwood, 10-20 parts of turmeric, 10-20 parts of selfheal, 10-20 parts of umbellate pore fungus, 10-20 parts of magnolia vine fruit, 10-20 parts of curcuma zedoary, 10-20 parts of tuckahoe, 10-20 parts of eclipta, 10-20 parts of root of red-rooted salvia, 10-20 parts of white peony root, 10-20 parts of barbed skullcap herb, 10-20 parts of baical skullcap root, 10-20 parts of epimedium, 1-10 parts of toad venom and 1-10 parts of scorpion. The traditional Chinese medicine preparation for treating liver cancer has the beneficial effects of prolonging the life time of inoperable patients, playing an adjuvant treating effect on patients treated mainly by operation, radiation treatment and chemo-treatment, and having certain curative effects on liver cancer-specific backgrounds of liver diseases such as hepatitis and liver cirrhosis.

The invention discloses a memory improving mixture separated from blood plasma and a preparation method and application of the memory improving mixture separated from the blood plasma. The mixture comprises various proteins and various micromolecules, SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) of the mixture comprises at least 30 bands, and the bands with molecular weights larger than 48kD include seven evidently visible bands with the molecular weights being 56kD, 68kD, 77kD, 115kD, 175kD, 250kD and 289kD sequentially. The preparation method of the mixture includes steps of blood plasma collection, density gradient centrifugation, dialysis, primary concentration, high-abundance protein removal, anion exchange and secondary concentration. The mixture prepared according to the method not only has a memory improving function but also can be used for preventing, improving and treating Alzheimer's disease.

The invention relates to a knowledge base establishing system and method based on old people care guide and disability and dementia. The knowledge base establishing system comprises a data acquisitionterminal, a data calculation center and a cloud end. The cloud end generates a first change trend set of a disability characteristic data set relative to the change of disability historical data based on the disability historical data; and / or the cloud end generates a second change trend set of a dementia feature data set relative to the change of dementia historical data based on the dementia historical data. The system comprises a care guide library in which at least two care measures are stored, so that the data calculation center can match the care measures corresponding to the change trend sets triggering the triggering conditions from the care guide library under the condition where at least one of the first change trend set and the second change trend set triggers the correspondingtriggering conditions.

The invention discloses an electric nasal cavity sampling and spraying device which comprises a flushing fluid container, an upper cover, an electric control panel, a water pressing pipe and a water diversion pipe. The upper cover is detachably connected to an opening of the flushing fluid container. The upper portion of the upper cover is provided with a conical liquid outlet. The liquid outlet is connected with the water diversion pipe with the lower portion extending into the flushing fluid container. The electric control panel is connected to the inner side of the upper cover in a sealed waterproof mode. The electric control panel comprises a battery, a driving pump, a control unit and a switch assembly. The output end of the driving pump is connected with a water pressing pipe with the lower portion extending into the flushing fluid container. A charging port of the battery and a control button of the switch assembly are fixed to a slot formed in the upper cover in advance. The upper cover is provided with an inner cover for protecting the electric control panel. The inner cover is stuck to the upper cover in an interference fit mode. According to the electric nasal cavity sampling and spraying device, the output air pressure of the driving pump is electrically controlled, flushing fluid is pressed out by means of the pressure difference to flush the nasal cavity of a patient, and a virus sample flows out of the nasal cavity on the other side under the circulated flushing. Flushing is carried out through the flushing fluid, the patient feels more moist, more comfortable and moderate and has no drying or stimulation feeling, and the nasal mucosa is not damaged.

The present invention provides therapeutic and / or prophylactic method comprising administering to a subject an amount of a composition sufficient to reduce or deplete antibody producing cells and / or prevent expansion of said cells in a tissue or organ of a subject suffering from T cell mediated autoimmune disease e.g., type 1 diabetes, or at risk of suffering from said disease, preferably wherein the composition is administered immediately prior to or concomitant with an autoimmune response. The present invention also provides the use of said composition in the manufacture of a medicament for the treatment and / or prevention of T cell mediated autoimmune disease. The present invention also provides said composition for use in the treatment and / or prevention of T cell mediated autoimmune disease.

The invention discloses a wearable intelligent monitoring device, comprising a wearable carrier such as an ear hanger, glasses, glue sticker, bandage, etc. and a conversion module arranged in the wearable carrier. The wearable intelligent monitoring device comprises a wearable carrier such as an ear hanger, glasses, glue sticker, bandage, etc. Module one includes control chip, Bluetooth chip, battery, two-color LED indicator, nine-axis and vibration sensor, vibration motor, buzzer. Module 2 includes control chip, Bluetooth chip, polymer lithium battery, two-color LED indicator, nine-axis and vibration sensor, ECG monitoring module. Module 3 includes a control chip, a Bluetooth chip, a polymer lithium battery, a two-color LED indicator, an EMG & MMG monitoring module, a vibration and audioacquisition chip, and a directional sound collector. The device has the advantages of simple structure, comprehensive function and strong universality, and ensures that the user maintains a healthy posture under various conditions and has monitored the disease condition of the patient through the accurate detection of the changes of the curvature degree of the head, neck and lumbar vertebrae, thesound changes of the joint wear and tear, and the related nerve and cardiopulmonary function.

The invention belongs to the technical field of biomedical science, and relates to a hypoxia-inducible chimeric antigen receptor capable of achieving specific activation of a tumor microenvironment. The structural domain of the hypoxia-inducible chimeric antigen receptor comprises: (1) one or more structural domains with specific combination of target antigens; (2) a structural domain in an extracellular spacer region; (3) a transmembrane structural domain; (4) one or more costimulatory signal structural domain and a cytokine receptor signal-transduction structural domain; (5) an intracellularsignal-transduction structural domain; and (6) an oxygen-dependent degradation structural domain. Once the hypoxia-inducible chimeric antigen receptor is exposed to an anoxic environment, efficient expression of the Hi-CAR on effect cell membranes is achieved, and specific recognition of target antigens is achieved, so that the specific activation property of the anoxic microenvironment is achieved; and since the anoxic situation of the tumor microenvironment is more significant than that of normal tissue, damage to the normal tissue can be reduced significantly, and meanwhile the activity ofspecific killing of tumors is improved.

The present invention relates to conjugates including a residualizing linker, methods for their production, and uses thereof.

An artificial intelligence guiding system for cornea crosslinking comprises the components of an ocular surface dispersed light image acquisition system which is configured for acquire a user ocular surface dispersed light image and sufficiently reflects cornea information; a cornea topographical map generating system which is pre-trained for converting the ocular surface dispersed light image toa corresponding cornea topographical map; a cornea crosslinking guiding system which is pre-trained for outputting a parameter required for a crosslinking surgery through comparison between a before-crosslinking cornea topographical map and an expected postoperative cornea topographical map; an ocular surface dispersed light image and corresponding cornea topographical map database which is used for storing an image pair of the ocular surface dispersed light image and the cornea topographical map and is used for pre-training a model and continuously correcting the model; and a cornea topographical map and cornea crosslinking parameter corresponding database which is used for recording the influence of the cornea crosslinking parameter to the cornea topographical map and performs a re-correcting function on the crosslinking guiding system. The artificial intelligence guiding system can greatly improve efficiency, accuracy and stability in a cornea crosslinking surgery process and reduces errors caused by subjective determining of a doctor.

The invention discloses a healthy seasoning for hypertension patients, which is prepared by the following materials by weight part: amomum fruit 2-3 parts, dahurian angelica root 2-3 parts, rhizome kaempferiae 2-3 parts, oriental blueberry leaf 2-3 parts, wrinkled giant hyssop 2-3 parts, banksia rose 4-6 parts, shitake mushroom 8-12 parts, straw mushroom 6-10 parts, oyster mushroom 6-10 parts, tremella 6-9 parts, auricularia 8-12 parts, wolfberry 8-12 parts, chrysanthemum 8-12 parts, cassia seed 8-12 parts and corn silk 8-12 parts. The components of the invention can not only be used for seasoning but also be helpful for improving appetite, harmonizing the center, drying dampness, benefiting the liver and kidney and improving the immunity of the hypertension patients and alleviating the disease condition. The common materials which have adverse effects for hypertension, such as chinese prickly ash, pepper, capsicum, fructus foeniculi, ginger, dried orange peel are taken off, and some materials which are useful for decreasing blood pressure, reducing blood lipid, and preventing arteridsclerosis, such as shitake mushroom, straw mushroom, oyster mushroom, tremella, auricularia, auricularia, wolfberry, chrysanthemum, cassia seed, corn silk and the like are added.

The present invention relates to methods and compositions for the treatment of neuropsychiatric conditions (e.g., bipolar disorder) by administration of prostaglandin or prostaglandin derivatives (e.g., latanoprost) to a subject (e.g., a human).

The present invention is related to the treatment of demyelinating and autoimmune diseases, more particularly with the treatment of multiple sclerosis. The treatment consists of the administration of P2X purinergic receptors antagonist substances which cause a remission of the symptoms common to these types of diseases. This is demonstrated in in vitro cell models as well as in animal models.

Provided are methods for extraction of various agents, e.g. active agent, from a plant source, specifically with the use of extraction formulations which are based on micellar liquid systems.

The present invention provides novel clustered multi-antigenic constructs having the structure:and methods for the synthesis thereof. In still another aspect, the present invention provides methods for the treatment of cancer, preferably for the prevention of recurrence of cancer, and methods for inducing antibodies in a subject, comprising administering to a subject in need, an effective amount of any of the inventive constructs as disclosed herein, either in conjugated form or unconjugated and in combination with a suitable immunogenic carrier.